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Abstract The development of formulations with thera-
peutic peptides has been restricted to poor cell penetration
and in this attempt; we developed pACC1 peptide loaded
chitosan nanoparticles. The prepared nanoparticles were
characterized with FT-IR, XRD, SEM and TEM. In addi-
tion, the suitable formulation was evaluated for hemo-
compatibility, plasma stability and embryo toxicity using
Danio rerio embryo model. The results showed that
pACC1 peptide loaded chitosan nanoparticles were com-
patible with plasma. They possess sustained release pattern
and also found to be safe up to 300 mg/L in embryo tox-
icity tests. Cytotoxicity assays with MDA-MB-231 cell
lines suggested that, pACC1 peptide loaded chitosan
nanoparticles were capable of enhanced cellular penetra-
tion and reduced palmitic acid content, which was con-
firmed by H1 NMR. Hence, these nanoparticles could be
employed as excellent adjuvant therapeutics while treating
solid tumors with multi-drug resistance.
Keywords Peptide pACC1  Chitosan  Nanoparticles 
Danio rerio  Cytotoxicity  NMR H1
Introduction
Nowadays, most of the drugs developed with the aid of
biotechnology intend to bind to a protein target, which may
alter the protein’s behavior. Protein interactions crucially
mediate many biochemical pathways in controlling cellular
proliferation and apoptosis. It has been endorsed that such
interactions hold great therapeutic potential for the devel-
opment of anti-cancer drugs. Peptides are highly suitable
candidates for cancer targets because of advantages like
small molecular size, simplicity associated with synthesis
and modification process, tumor penetrating potential and
biocompatibility. However, peptides also demonstrate
some critical drawbacks, such as short plasma half life,
poor oral bioavailability and different administration routes
that could affect their pharmacokinetics and biological
activities (Borghouts et al. 2005). Nanoparticles possess
higher ability in delivery of proteins and nucleic acids
principally into tumor cells, and moreover, they can pref-
erentially accrue in the tumor tissues greater than what they
do in normal tissues. This phenomenon is a significant
advantage with regard to cancer targeted drug delivery
(Grant and Leone-Bay 2012). Under pathological condi-
tions, leakiness of tumor vasculature is a positive prospect
for facilitating tissue penetration of nanoparticles. In
addition, the nanoparticles facilitate the endosomal escape
(Grant and Leone-Bay 2012; Matsumura and Maeda 1986;
Erazo-Oliveras et al. 2012). Thus, the above mentioned
drawbacks could be overcome by the peptides with the help
of nano carriers. The selection of a biocompatible polymer
is an imperative step in the delivery of peptides in an
effective manner. Principally, they yield a constant release
with a simple monolithic device; the slow matrix degra-
dation can retain the levels of peptides in plasma, thereby
increasing the permeability of peptides in tissues. Existing
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literature has confirmed that up-regulation of de novo
lipogenesis in cancer cells is a crucial phenomenon that
happens spontaneously to satisfy the energy demand (Shen
and Tong 2008). Recently, the peptide pACC1 (sequence
from acetyl-CoA carboxylase 1 1258–1271aa) has been
identified and considered as a novel binding partner for the
BRCT domain of the BRCA1 in a phosphorylation-de-
pendant manner (Magnard et al. 2002; Ray et al. 2006;
Brunet et al. 2008). This interaction might address its
greater therapeutic value in suppressing cancer cell pro-
liferation by blocking membrane synthesis and saturation
through inhibiting fatty acid biosynthesis. In the present
investigation, peptide pACC1 was checked for the com-
patibility with different polymers, chitosan based peptide
pACC1 polymeric nanoformulation was developed and
reported first time for their biocompatibility and cytotoxi-
city using MDA-MB-231 cells lines.
Materials and methods
Materials
Synthesized custom peptide pACC1 was procured from
BioConcept Labs (Delhi, India). HPLC grade chemicals
were purchased from Merck Millipore (India). Gelatin
(type A), sodium alginate, chitosan (medium molecular
weight) and sodium tripolyphosphate were purchased from
Sigma Aldrich (Bangalore, India). Cell culture media
(RPMI-1640) and fetal bovine serum (FBS) were pur-
chased from GIBCO/BRL Invitrogen (Caithershurg, MD).
Trypsin, methylthiazolyldiphenyl-tetrazolium bromide
(MTT), and dimethyl sulfoxide (DMSO) were purchased
from (SISCO research laboratory chemicals Mumbai). All
other chemicals used were of analytical grade.
Preparation of nanoparticles
With an objective to evaluate the polymer peptide com-
patibility, the pilot study was carried out with three peptide
compatibles.
pACC1-Chitosan nanoparticles
Chitosan nanoparticles were prepared by ionic crosslinking
of chitosan with sodium tripolyphosphate (TPP) anions
(Haliza Katas et al. 2012). Chitosan (2 mg/mL) was dis-
solved in acetic acid (0.25 % v/v) with constant stirring at
10 C. Aqueous solution of TPP (0.75 % w/v) was added
(2:1 ratio) into chitosan solution containing 100 lg/ml of
pACC1 peptide with continuous stirring for 6 h. The
resultant dispersion was centrifuged at 13,0009g for
20 min at 4 C. The supernatant was then removed and
peptide chitosan nanoparticles (PCN) were collected and
freeze-dried (-55 C).
pACC1-gelatin nanoparticles
Gelatin peptide nanoparticles (GPN) were prepared by two-
step desolvation method with slight modifications (Azimi
et al. 2014; Ofokansi et al. 2010). Briefly, gelatin (100 mg)
was dissolved in distilled water (5 mL) under constant
heating at 37 C and adjusted to pH 4. pACC1 peptide
(1 mg) was added into the gelatin solution followed by
acetone (12 mL). Further, aqueous solution of glutaralde-
hyde (25 % v/v) was added as a crosslinking agent and the
solution was stirred continuously for 6 h at 4 C. The
resultant was sonicated (sonitvibra cell, UC130, USA,
amp-20, pulser-5 s) and centrifuged (13,0009g) for 30 min
at 4 C. The particles were washed with distilled water and
freeze-dried.
pACC1-sodium alginate nanoparticles
Sodium alginate peptide nanoparticles (SPN) were pre-
pared by controlled ionic gelation method (Catarina et al.
2006; Saeed et al. 2013). Briefly, 2 mL of calcium chloride
(18 mM) was added to 38 mL of sodium alginate solution
(0.1 % w/v) to promote gelation. Ten milliliters of peptide
pACC1 (0.1 % w/v) was added to calcium alginate solution
to form nanoparticles. The suspension was stirred for 2 h
and kept overnight for stabilization. The nanoparticles were
subjected to centrifugation (13,0009g) for 45 min at 4 C.
Peptide polymer compatibility study
The interaction between pACC1 peptide and polymer was
conferred with FT-IR (Perkin Elmer, Spectrum-RX1, USA)
spectra in range of 400–4000 cm-1. X-ray diffraction
studies were performed for chitosan and PCN to confirm
the non existence of crystalline structure.
Characterization of PCN
The Chitosan nanoparticles were formulated by keeping
constant peptide pACC1 concentration and different ratios
of chitosan. Different concentrations of chitosan [0.1, 0.2,
0.3, 0.4, and 0.5 % (w/v)] were obtained by dissolving in
acetic acid (0.25 % v/v) under constant stirring (250 rpm)
overnight. Twenty milliliter of TPP 0.75 % (w/v) was
added into 10 mL chitosan solution containing 0.20 mg of
pACC1 peptide and stirring was raised to 320 rpm for 6 h
at 4 C. The resultant dispersion was subjected to sonica-
tion (Sonitvibra cell, UC130, USA, Amplitude-20, Pulser-
4 s) for 10 min at 4 C. Further, the dispersion was washed
thrice (22009g) and re-dispersed in HPLC grade water
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(LiChrosolv) and again centrifuged at 13,0009g for
20 min at 4 C to obtain five different peptide polymer
ratio formulations (PCN-J01 to PCN-J05). Finally, the
nanoparticles were freeze-dried (Delvac-lyo1550, INDIA)
and stored at -20 C for further characterization.
Process yield
The freeze-dried formulations (PCN-J01 to PCN-J05) were
weighed to calculate the process yield as previously
described (Nesalin and Smith 2012). The results were
expressed as mean values obtained from three replicates.
Association and loading efficiency
Association efficiency (AE) and loading efficiency (LE)
were calculated based on previous methods with slight
modification (Ma et al. 2002). PCN were pelletized at
58009g and supernatant was quantified for peptide by RP-
HPLC method developed in our laboratory (Jagatheesh
et al. 2014). The formulae mentioned below were used to
calculate AE and LE.
AE ¼ Total amount of Peptide Peptide in supernatant
Total amount of Peptide
 100
LE ¼ Total amount of Peptide Peptide in supernatant
Weight of recovered nanoparticles
 100
In vitro peptide release
In vitro release of formulations (PCN-J01 to PCN-J05) was
determined by plasma simulation (Narayanan et al. 2013)
and dialysis membrane method (Hu et al. 2002) with slight
modifications. Briefly, the formulations was redispersed in
10 mL of NaCl (0.9 % w/v) with final peptide concentra-
tion of 20 lg/mL. One milliliter of the above mentioned
mixture was added to 10 mL of PBS (0.5 M, pH 7.4) and
10 mL of suspended blood cells were added. The suspen-
sion was kept in orbital shaker at 37 C. One milliliter of
released solution was collected at different time intervals
and replaced with fresh solution. The harvested solutions
were centrifuged and supernatant was used to analyze
peptide content by RP-HPLC (Jagatheesh et al. 2014). The
release rate was calculated using following equation
Peptide release %
¼ Amount of Peptide released at time ‘‘t
00
Amount of Peptide loaded in the naoformulation
 100
In dialysis membrane method, 2 mg of formulations
(PCN-J01 to PCN-J05) was redispersed in 10 mL of PBS
(0.5 M pH 7.4), placed in dialysis membrane (cut-off
10 kDa) and dialyzed against PBS (0.5 M pH 7.4). Two
milliliter of released solution was collected at different
time intervals, replaced with fresh solution and analyzed by
RP-HPLC by calibration curve method.
Particle size distribution and zeta potentials
The size distribution and zeta potentials of formulations
(PCN-J01 to PCN-J05) were measured by Zeta Sizer
(Malvern, Mastersizer 2000, UK). Sample was dispersed in
water (pH 7.4) and the particles were counted in 4.8 mm
calibrated area with the count rate of 210.3 Kcps for 70 s.
The analysis was performed in triplicates and mean values
were reported.
Kinetic modeling
To determine the suitable drug release kinetic model
describing the mechanism dissolution profile, the result of
in vitro release obtained from two methods were fitted with
various kinetic equations such as zero order, first order,
Higuchi’s model and Peppas plot methods (Dash et al.
2010).
Surface morphology
Scanning electron microscopy (TESCAN, VEGA3 SBU,
Czech) of the chitosan nanoparticles were performed to
observe the particle size and surface morphology. The size
and shape of the nanoparticles were further characterized
using the transmission electron microscope (Jeol,
JEM2100, Japan).
Hemocompatibility
Hemocompatibility was evaluated as previously reported
(Pooja et al. 2014), using Triton X-100 (1 %) and normal
saline as negative and positive control, respectively.
Embryo toxicity
The Danio rerio was maintained as female/male (2:1 ratio)
in 23 9 30 9 23 cm glass aquarium at an average temper-
ature of 26 ± 1 C and 14 h/10 h light dark cycle (Zhu et al.
2008). The spawning was goaded in the morning 6–7 (?5.30
GMT). After 30 min, the embryos were collected and
maintained in E3 medium. Healthy embryos (n = 96) were
collected and exposed to PCN-J04, 4–5 h post fertilization.
Each well contained 12 embryos with different concentra-
tions of PCN-J04 (1, 3, 10, 30, 100, 300, 1000 mg/L).
Throughout the experiment, the developmental status of the
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Danio rerio embryos and larvae was observed under com-
poundmicroscope (Olympus,MLXi, Japan) at different time
intervals. The toxicity was assessed with multiple parame-
ters such as embryo/larva survival, hatching rate and mal-
formations including tissue ulceration, pericardial edema
and body arcuation.
Plasma stability
Fresh blood (Wister rat) was collected in heparinized tubes
and plasma was separated by centrifugation (18009g for
15 min at 4 C). Separated plasma was incubated at 37 C
for 30 min in 0.9 % w/v of NaCl solution and PCN-J04
(10 lg) was added. At regular intervals, plasma solution
(1 mL) was collected and stored at -20 C until use. After
centrifugation (17,0009g 20 min), peptide content was
analyzed by HPLC (Jagatheesh et al. 2014).
In vitro Cytotoxicity
Human breast cancer MDA-MB-231 (GDC055) cell lines
were obtained from National Center for Cell Science, Pune
(NCCS). The cells were maintained in RPMI-1640 sup-
plemented with 10 % FBS, penicillin (100 U/mL), and
streptomycin (100 lg/mL) in a humidified atmosphere of
5 % CO2 at 37 C.
The cytotoxicity of PCN-J04 on MDA-MB-231 cells
was determined by the MTT assay (Lagopati et al. 2014).
Cells (1 9 105/well) were plated in 100 ll of medium/well
in 96-well plates. 80 % confluence of cells was incubated
in the presence of various concentrations of the PCN-J04 in
DMSO (0.1 %) for 48 h at 37 C. After removal of the
medium, cells were washed with PBS (pH 7.4) and incu-
bated with MTT for 4 h. Viable cells were determined by
the absorbance measured at 570 nm with microplate reader
Fig. 1 FT-IR spectra for polymer peptide compatibility: a Gelatin–
peptide pACC1 compatibility. Black manifestation shows the peptide
pACC1, red manifestation denotes FT-IR spectrum of gelatin, green
manifestation shows FT-IR spectrum of glutaraldehyde (Cross linker)
and blue manifestation shows FT-IR spectrum of GPN; b FT-IR
spectra for sodium alginate–peptide pACC1 compatibility; c FT-IR
spectra for chitosan–peptide pACC1 compatibility and d XRD
Spectrum of chitosan and chitosan peptide pACC1 nanoparticles
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(Bio-Rad, USA). The effect of the samples on the prolif-
eration of human breast cancer cells was expressed as the
% cell viability, using the following formula:
% cell viability ¼ A570 of treated cells=A570 of control cells
 100 %
The optimum dose of PCN-J04 was fixed based on 50 %
inhibitory concentration.
Apoptosis analysis using duel staining
The cells were plated at a density of 5 9 104 in 6-well
plates and were allowed to grow till 80 % confluence.
Then, cells were treated with different concentrations of
PCN-J04 for 24 h. The culture medium was aspirated from
each well and cells were gently rinsed twice with PBS and
subsequently treated with 100 ll of ethidium bromide and
acridine orange (1:1 w/w) (Kasibhatla et al. 2006). Viewed







AE (%) LE (%) Z average
(day nm)
PDI (Ð) Zeta potential
(mV)
J01 1:0.5 50.60 ± 1.44 41.150 ± 1.65 35.474 ± 2.43 322.9 ± 22 0.287 ± 0.023 ?37 ± 2.9
J02 1:1 80.25 ± 4.00 47.715 ± 2.69 50.760 ± 3.22 368.1 ± 25 0.345 ± 0.032 ?31 ± 2.7
J03 1:1.5 79.63 ± 3.34 61.110 ± 2.76 53.371 ± 2.34 397.6 ± 21 0.245 ± 0.042 ?35 ± 3.4
J04 1:2 83.57 ± 3.56 61.170 ± 2.97 58.535 ± 3.98 402.7 ± 33 0.199 ± 0.012 ?39 ± 2.4
J05 1:2.5 87.23 ± 4.60 66.161 ± 2.39 62.712 ± 1.99 532.3 ± 27 0.406 ± 0.033 ?36 ± 3.2
All values were expressed mean of three replicates with ±SE
Fig. 2 Representation of intermolecular hydrogen bonding between peptide pACC1 (=O) and chitosan (HO)
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immediately under Fluorescence Microscope (Olympus,
MLXi, Japan). The percentage of apoptotic cells was
determined as follows:
% of apoptotic cells
¼ total number of apoptotic cellsð
=total number of cells countedÞ  100
Estimation of lipids by H1 NMR
Eighty percentage confluence of cells were incubated in
presence of 7.66 lg/mL of final concentration of peptide
containing PCN-J04 for 48 h, and the cellular lipids were
isolated by previously described method (Folch et al.
1957). The freeze-dried samples of control and PCN-J04
treated cellular lipids were used for one dimensional H1
NMR spectrum by dissolving in 600 lL of Acetone-d6
(Merck KGaA, Germany) and spectrum acquired with
300 MHz AVANCE II (Bruker BioSpin, Switzerland)
spectrometer equipped with a 5 mm BBO probe (Bruker
BioSpin, Switzerland). The experiments were recorded at
297.15 K using the standard pulse sequence library of
TopSpin 1.3 (Bruker BioSpin, Switzerland) followed by
processing of the data by using TopSpin 1.3 (Bruker
BioSpin, Switzerland) software. The H1NMR spectra of
control and PCN-JO4 were overlaid and the difference
spectra were arrived using the tool available in TopSpin
and the comparison was made with the identical scaling
factor.
Statistical analysis
All the above experiments were performed thrice inde-
pendently, with triplicates. The statistical analysis was
performed using Graphpad prism (version 5.0). Results
were expressed as mean ± SE. The standard error values
are indicated as error bars in the corresponding graphs.
Two way analysis of variance (ANOVA) with Bonferroni
post-tests comparisons was used to detect the significance




The FT-IR spectrum (Fig. 1a–c) shows multiple polymers
and their interactions with peptide. The spectra of peptide
(Fig. 1a) show significant peaks at 3432 cm-1(O–H
stretching), 1633 cm-1 (C=N stretching), 1579 cm-1 (N–H
stretching) and 1402 cm-1 (C=O stretching). In chitosan
spectra (Fig. 1c), the peaks were observed at 3392 cm-1
(N–H stretching), 1574 cm-1 (N=N stretching) and
1462 cm-1 (C=C stretching). The PCN spectra show sharp
peak at 3408 cm-1(O–H) and 1402 cm-1(C=O) (Fig. 1c).
The broadening of peak at 3408 cm-1 was due to the
intermolecular hydrogen bonding between chitosan and
peptide. According to Flory–Huggins theory (Flory 1953),
the intermolecular hydrogen bonding in PCN (Fig. 2) has
been attributed to the strong interaction between hetero
atoms and the carbonyl of amide (C=O–HO). The absence
of peak at 1400–1600 cm-1 (C=O stretching) in GPN
might be due to ionic bonding between polymer and pep-
tide. The spectrum of sodium alginate was observed in the
peak range of 1400–1600 cm-1 but the peak broadening
(Fig. 1b) was not appreciable as compared to PCN. Hence,
it might be suspected as very weak interaction (van der
Fig. 3 In vitro release profiles of pACC1 peptide from different formulations estimated by plasma simulation method; b release profile of
peptide pACC1 from formulations predicted by dialysis membrane method m values are expressed ±SE of three replicates
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Waals interactions) between the groups, possibly due to
lack of electro negativity.
Collectively, chitosan was found to be extremely com-
patible polymer with an ability of formation of inter-
molecular hydrogen bond. Hence, further studies were
carried out with PCN.
Optimization of peptide polymer ratio
The present investigation was to find the effective peptide
polymer ratio, by keeping constant peptide concentrations
and variable chitosan concentrations. To find the ratio, the
amount of peptide per unit of polymer was greater which
might result in higher yield and efficiency. The result of
process yield of formulations (PCN-J01 to PCN-J05) was
found to be directly proportional to polymer ratio. The ratio
of peptide and polymer (1:2.5 w/w) showed higher degree
of process yield when compared with other peptide poly-
mer ratio, due to greater carbon efficiency (Table 1).
Interestingly, the association and loading efficiencies of
formulations increased with an increase in peptide polymer
ratio (1:2.5). The greater association and loading efficien-
cies were due to reduced pH (6.5) experimental condition.
Hence, the positively charged chitosan (pKa *6.5) might
depict greater attraction with negatively charged
pACC1(-2).
Table 2 Release kinetics and mechanism of drug release
Batch code Cumulative drug release (%) Zero order First order Higuchi plot Peppas plot n value Hixsson
Simulated blood plasma method
J01 84.35 0.837 0.569 0.936 0.792 1.081 0.040
J02 82.20 0.737 0.410 0.883 0.646 0.977 0.059
J03 78.37 0.734 0.449 0.882 0.687 0.977 0.067
J04 68.83 0.757 0.450 0.902 0.702 0.965 0.087
J05 62.15 0.538 0.407 0.726 0.640 0.910 0.099
Dialysis membrane method
J01 89.35 0.726 0.376 0.907 0.562 0.869 0.028
J02 82.30 0.660 0.356 0.847 0.559 0.854 0.069
J03 78.35 0.741 0.390 0.904 0.593 0.861 0.070
J04 68.85 0.767 0.391 0.924 0.589 0.816 0.089
J05 66.00 0.612 0.428 0.788 0.660 0.930 0.092
Fig. 4 Surface morphology of PCN-J04. a SEM image shows typical nanoparticle distribution of PCN-J04; b TEM image of PCN-J04 showing
particle size of 200–300 nm
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The mean particle size of formulations (PCN-J01 to
PCN-J05) obtained by zeta seizer ranged from 322 to
532 nm; this greater particle size when compared to TEM
analysis (200–250 nm) might be due to swelling and
formation of good polymeric networks of chitosan in the
polar medium (water). The Polydispersity index (PDI) of
formulations (PCN-J01 to PCN-J05) was maintained on
an average between 0.287 and 0.406. Formulation J04
possessed less PDI of 0.199 when compared with all other
peptide polymer ratios. The DLVO theory states that
stability of particle in the dispersion depends on the
balance between attractive and repulsive forces among the
particles (Lin et al. 2014). Hence, the particles with
PDI\0.5 are considerably stable, lesser agglomeration
and travel faster in the circulatory system. As a result,
PCN-J04 displayed the capability to produce faster onset
of action and was comparatively stable with other for-
mulation batches. Further, all the formulations batches
were positively charged between ?36 and ?39 mV.
Evidently, the cancer cell surfaces are usually negatively
charged due to translocation of negatively charged con-
stituents in the inner layer cell membrane such as phos-
phatidylserine, anionic phospholipids, glycoproteins and
proteoglycans. Owing to the negative charges in the inner
layer of cell membrane, tumor vasculature might have
potentiated the electrostatic interaction between positively
charged nanoparticles and negatively charged tumor cells.
This might be responsible for the tumor-specific accu-
mulation. In addition, the positively charged nanoparticles
were retained for a longer time span in the tumor site
when compared to negative or neutral particles. Since
phosphatidyl serine is a negatively charge residue, it gets
translocated to the surface of cancer cells.
In vitro release determination
The results of formulations (PCN-J01 to PCN-J05) release
pattern showed (Fig. 3b, m) not much of variations in
plasma simulation and membrane dialysis methods. The
increased size of PCN decreased the rate of peptide release
in 25 h pattern. The 50 % release of peptide content was
achieved between 3 and 10 h in most of the formulations.
The results of the present study showed that increased AE
was inversely proportional to the peptide release. Further,
the study results showed that there is no ‘burst’ effect in
both plasma simulation and membrane dialysis methods of
in vitro release which assured that the formulations were
not weakly bound. All formulations followed Higuchi
diffusion with regression values ranging between (0.788
and 0.96). Hence, it can be hypothesized that preponder-
ance release of peptide is accommodated by diffusion.
Principally, Higuchi diffusion-driven release into the
matrix was unaltered and it could be assumed that rate of
solubility of chitosan exerted an influence in the release of
peptide. Further, the swelling of the polymer favored single
pore formation, through which sustained release would be
achieved. On the whole, the formulation PCN-J04
encompassed fair AE, zeta potential and good release lin-
earity. Hence, further studies were carried out with PCN-
JO4 (Table 2).
Characterization of PCN-J04
The XRD spectrum (Fig. 1d) of chitosan showed a sharp
peak in 23h and the PCN did not have any sharp peaks over
XRD. Sequentially, the peak got broader and there was a
radical fall in height. This might be attributed to the fact
that particles undergo microstress, obtain grain boundaries
Fig. 5 Percentage hemolysis leads on treatment of different concen-
tration of PCN-J04. Values are expressed ±SE of three replicates
Fig. 6 Plasma liberation of peptide pACC1 at different time intervals
form PCN-J04. Values are expressed ±SE of three replicates
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and sub-boundaries. According to law of Scherrer (Singh
2005), the shortening and peak broadening are evidences
that the particles had gained nano-scale status. The ultra
structural images of PCN-J04 (Fig. 4a, b) shows spherical
shape particles, although appeared to be a little aggregated.
This indicates that the incorporation of peptide as a solid
structure contributed to the enhancement of morphology of
nanoparticles. Further, there was no shearing on the surface
of PCN-J04 due to the formation of intermolecular
hydrogen bonding in multiple regions.
Hemocompatibility of PCN-J04
The results showed that the damage of the erythrocytes by
PCN-J04 was insignificant even at higher concentrations
(14 lg/mL) which might not be the case in normal therapy.
Further, the increase in concentration of PCN-J04
increased the hemolytic property (Fig. 5). The reason
might be chitosan interacts with the negatively charged
membrane of erythrocytes by electrostatic attraction and
triggers thrombus formation (Fig. 6).
Plasma stability of PCN-J04
The results of plasma stability studies for PCN-J04 were
represented in Fig. 7. Results showed that PCN-J04 remain
stable more than 60 min from chemical (acids) and enzy-
matic degradation which is suitable for nanoparticles to
target tumor tissue. It is believed that movements of
nanoparticles are fast when compared to macro molecules.
Hence, it would reach the tissue compartment from central
compartment within 60 min. Further, the vascular leakage
might also facilitate the nanoparticles entry into the tumor
micro environment.
Embryo toxicity assessment
In the present investigation, the survival rate of larvae
decreased with increasing concentration of PCN-J04 in the
medium. The survival rate declined from 300 mg/L, but
more than 50 % reduction was observed in 1000 mg/L.
The death rate of larvae was observed between 48 and 72 h
when compared to control (Fig. 7a). The hatching rate of
Fig. 7 Embryo toxicity of PCN-J04. a Effect of PCN-J04 on Danio rerio embryo survival rate; b hatching rate; c, d percentage of surviving
larvae with different deformities; values are expressed ±SE of three replicates, **p\ 0.05 vs pairs of columns
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larvae from chorionic membrane in all the concentrations
of PCN-J04 and control occurred between 36 and 50 h. The
300 and 1000 mg/L treated group showed significant delay
in the percentage of hatching rate but the maximum
hatching rate was observed in 60–72 h (Fig. 7b).
There is no tangible statement suggesting that Danio
rerio genome has BRCA1 orthologue. But it does have an
orthologue of the BRCA1-associated BARD1 gene, which
encodes an associated and functionally similar protein
which has interacting ability with pACC1 similar to the
BRCT domain. The Danio rerio embryo develops under
higher proliferation rate with low oxygen environment.
Considering the above facts, we hypothesized that it may
switch over to de novo lipogenesis similar to the cancer
cells.
The survival rate decreased with high concentrations of
PCN-J04 exposure due to pore size enlargement of chorion
which might benefit the entry of larger amount of nano
particles. Large dose of nanoparticles might drive toxic
amounts of thermal energy which could lead to lethality.
Further, the delay in hatching with higher concentration
might be attributed to the hindrance in growth of gill
filaments due to extreme starvation of nutrients (lipids).
Furthermore, the nanoparticles that enter into the body
might show cytotoxic and immunotoxic effects due to the
distribution of the nanoparticles in the body. This might be
similarly useful when tumor tissues are targeted. However,
the heat shock proteins could be induced by PCN-J04
might potentially damage the cell by disturbing many
cellular processes including protein synthesis, folding,
translocation, and assembly of larger protein complexes, all
of which could be impaired by stress. The tail deformity,
pericardial edema, yolk sac edema and tissue ulceration
(Fig. 8) were observed with increasing concentrations of
PCN-J04 (Fig. 7c, d). This could be due to the absence of
Elovl2 protein. The Elovl2 protein has vital functions such
as fatty acid elongase and transferase activities (acyl group
to amino-acyl). The regulation of Elovl2 depends on
amount of fatty acids synthesis and BARD1 phosphoryla-
tion (Chen et al. 2013; Monroig et al. 2009). Thus, the
authors have proposed a hypothesis that the action of
pACC1 in regulating fatty acids biosynthesis might directly
influence the level of Elovl2 expression in Danio rerio. The
homeostasis in the expression of Elovl2 was maintained in
Fig. 8 Deformities of embryo–larvae. a Larvae with body arcuation deformity; b control larvae without any deformity; c, d larvae with tissue
ulceration; e unhatching matured larvae; f, g pericardial and yolk sac edema; h, i tail deformity larvae
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the lower levels of PCN-J04, but in higher concentration,
the expression could be expected to be decreased.
The delayed action of PCN-J04 on Danio rerio might be
due to sustained release of peptide. Further, lethality in
higher concentration might be due to metabolic distur-
bances; in lower concentrations, auto correction might be
achieved by embryos.
Effect of PCN-J04 on cell viability
The dose-dependent effect of PCN-J04 on cell proliferation
was examined by the MTT assay. MTT is reduced by living
cells and the resultant formazan product is proportional to
the cell viability. The PCN-J04 treatment (5, 10, 15, 20 and
25 lg/mL for 24 h) on MDA-MB-231 cells induced a dose-
dependent cytotoxicity, with approximate IC50 value of
6.37 lg/mL (final concentration of peptide containing
PCN-J04) [Fig. 9A (g)]. The percentage of viable cells
treated with PCN-J04 significantly decreased when com-
pared to control [Fig. 9A (a–f)]. Tandem repeats of BRCT
domains can be found in BRCA1 and there is an option of
minimal aggregation that would contribute to faster relax-
ation in the Free State, as in pACC1 peptide complexes
BRCT domain. This amendment precisely correlated to our
results in which PCN-J04 possess the concentration
dependent apoptotic effect in MDA-MB-231 cells.
Fig. 9 A Influence of PCN-J04 in cell viability on MDA-MB-231
cell lines a control cells, b 5, c 10, d 15, e 20, f 25 lg/ml peptide final
volume containing PCN-J04 treated and g represents Percentage
viable cells; B PCN-J04 induced apoptosis on MDA-MB-231 cell
lines a control cells, b 5, c 10, d 15, e 20, f 25 lg/ml peptide final
volume containing PCN-J04 treated g represents percentage of
apoptotic cells
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Dual staining (acridine orange/ethidium bromide) was used
to evaluate the nuclear morphology including chromatin
condensation around the nuclear membrane of apoptotic
cells. The results discriminates yellow—early apoptosis
and orange/red—late apoptosis observed with PCN-J04
treated cells [Fig. 9B (a–f)]. Whereas, uniform bright green
live cells were seen in control. The percentage of apoptotic
cells was high in 10 lg/mL [Fig. 9B (g)] final volumes of
peptide containing PCN-J04.
PCN-J04 on lipid levels
The H1 NMR spectrum of control and PCN-J04 treated
cellular lipids were shown in Fig. 10. The tiny peak at
0.9 ppm belongs to –CH3 of palmitic acid which altered
signals in PCN-J04 treated cellular lipid fractions, and
there was no detectable acidic phospholipids signal in
both spectra. The variation in the overlaid H1NMR
spectra at 0.9 ppm can perhaps be attributed to reduction
in the palmitic acid contents in PCN-J04 treated cellular
lipid fractions.
Conclusion
The present study outlines the pharmaceutical characters
and biocompatible nature of pACC1 loaded chitosan
nanoparticles. The sustained release ability of PCN-J04
will be highly appreciated with in vivo conditions. Further,
it evidenced potent anti-tumorigenic effect on MDA-MB-
231 cells via lowering lipid levels. Hence, these nanopar-
ticles perhaps recommended as adjuvant therapeutics while
treating solid tumors.
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